Copenhagen, 2013-03-14 08:00 CET (GLOBE NEWSWIRE) -- Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) announces the launch of a new corporate branding platform and company logo which as of today can be viewed on the company’s website at www.zealandpharma.com.
Commenting on the new company branding, David Solomon, President and CEO of Zealand, said:
"We are pleased to launch ZEAL&, our new corporate branding platform and logo. Zealand, the name of the most populous island in Denmark is our home, but ZEAL& refers to who we are, a company devoted to discovering revolutionary medicines, to our zeal, our enthusiasm. Peptide Innovation is at our core but we cannot conduct our healthcare endeavors alone, however. So we are ZEAL& patients, ZEAL& partners, ZEAL& universities."
"2013 has begun on an extremely positive note with the European approval and first sales of Lyxumia®, our discovered medicine, partnered with Sanofi. We look forward to sharing more results, first our 2012 Full Year results and Annual Report today and more ZEAL& in the coming months."
# # #
For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689,
About Zealand Pharma
Zealand Pharma A/S ("Zealand") (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2013).
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information: www.zealandpharma.com
